Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Angion Biomedica

Request full access

Clinical stage organ restoration biopharmaceutical company focused on renal disease

Hempstead, United StatesFounded 1998Biotech & Life Sciences

About Angion Biomedica

Angion Biomedica Corp is a late-stage clinical company focused on developing small molecules aimed at treating acute organ injury and chronic fibrosis. The company's lead product, ANG-3777, is designed to activate the HGF c-Met pathway, a critical mechanism in organ repair. Angion's primary market includes patients suffering from acute kidney injury related to kidney transplantation and acute lung injury associated with COVID-19 pneumonia. The business model revolves around advancing its clinical trials to achieve regulatory approval, thereby enabling commercialization and partnerships with healthcare providers and pharmaceutical companies. Revenue is generated through the development and potential future sales of its therapeutic products, as well as possible licensing agreements. Angion operates in the biopharmaceutical sector, targeting unmet medical needs in organ injury and fibrosis.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
18
Open positions
None listed
Dealroom signal
26.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Surgery, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Investment activity
1 company, latest Jan 2023
Capital deployed
—
Preferred round
POST IPO DEBT

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jan 2023 $0 — Elicio Therapeutics ↗
IPO✓Exit Feb 2021 $0 — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Angion Biomedica website traffic

Latest recorded traffic for Angion Biomedica is 4.7K monthly website visits, up 147.4% over the last three months. Angion Biomedica's team declined 14.3% over the past year.

Latest monthly visits4.7K 3-month web change+147.4% 1-year team growth-14.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Angion Biomedica in the Hempstead ecosystem

Live from Dealroom

The Angion Biomedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Other known investors2 additional known investors

  • Elicio Therapeutics
  • Formic Ventures
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Angion Biomedica’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.